Making Cancer-Fighting Antibody Drugs Safer with Precise Attachment

This patent describes a specific way to build antibody-drug conjugates (ADCs) for cancer treatment by precisely attaching chemotherapy drugs to antibodies to make them safer inside the body.

What it covers

The patent describes an antibody drug conjugate (ADC) designed to deliver chemotherapy more safely. It combines an antibody (or a fragment of one) with an anthracycline-based small molecule, which is a type of chemotherapy drug (Claim 1). The key is how they are linked: the small molecule is *exclusively* attached to the C-terminus of the antibody's light chain constant region (Claim 1). This attachment uses a linker that includes a peptidic sequence, often formed after a sortase enzyme cleaves a recognition motif (Claim 3, 9). For example, the patent specifies that two anthracycline molecules are linked, one to each light chain C-terminus (Claim 1), ensuring a precise drug-to-antibody ratio. This design aims for improved tolerability in the body, particularly for treating neoplastic diseases like breast cancer (Claim 10, 11).

What it doesn't cover

• —ADCs where the drug is attached to parts of the antibody other than the light chain constant region C-terminus (Claim 1).
• —ADCs that use chemotherapy drugs *not* based on anthracycline (Claim 1, "anthracycline-based small molecule").
• —ADCs where the drug is linked via a method that does not involve a sortase enzyme or a peptidic sequence linker (Claim 1, 3, 9).
• —ADCs with a drug-to-antibody ratio different from 1 or 2, specifically if there are more than two anthracycline-based small molecules per antibody (Claim 1, "two light chain constant region C-termini and two anthracycline-based small molecules").
• —ADCs where the linker does not comprise a peptidic sequence (Claim 1).

The clever bit

The novelty lies in the highly specific and controlled attachment of the anthracycline-based chemotherapy drug. By exclusively linking the drug to the light chain constant region C-terminus using a sortase-mediated conjugation, the patent ensures a precise drug-to-antibody ratio (specifically two drugs per antibody) and a stable connection, which is crucial for improving the drug's safety and effectiveness in the body.

Why it matters

Antibody-drug conjugates (ADCs) are a major advancement in cancer treatment, acting like "guided missiles" to deliver potent chemotherapy directly to cancer cells while sparing healthy tissue. However, ensuring these drugs are stable and well-tolerated in the body is critical. This patent addresses the tolerability challenge by defining a precise and controlled way to attach the chemotherapy drug, potentially leading to fewer side effects for patients.

Real-world examples

• 1.NBE Therapeutics' own ADC candidates
• 2.Targeted cancer therapies for solid tumors
• 3.Next-generation antibody-drug conjugates